Sichenzia Ross Ference Kesner LLP Represents MabVax Therapeutics Holdings, Inc. on $4.1 Million Public Offering

mabvax therapeutics

Press Release – New York, NY – June 5, 2017 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, in a public offering of common stock and Series G Preferred Stock for a total of $4.1 million. Sold in the offering was a combination of common stock and Series G Preferred Stock at $1.75 per share of common stock and Series G Preferred Stock.

The Sichenzia Ross Ference Kesner LLP team was led by partners Harvey Kesner, Avital Perlman and Tara Guarneri-Ferrara and associate Evan Berger.

Sichenzia Ross Ference Kesner LLP

Sichenzia Ross Ference Kesner LLP

Sichenzia Ross Ference Kesner LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals.

Visit SRFK's LinkedIn page
Sichenzia Ross Ference Kesner LLP